Gilead Sciences

Cognizant seals $800 million deal with California-based Gilead Sciences

Agreement includes renewal and expansion of various IT services over next five years

Gilead announces steps to expand availability of Remdesivir in India

American biopharmaceutical company Gilead has announced steps to expand the availability of remdesivir, a key therapeutic medicine used in the treatment of Covid-19 patients, in India

Gilead to acquire German biotech firm MYR for about 1.15 billion euros

The deal will also include a potential future milestone payment of up to 300 million euros

WHO advises doctors against using Gilead's remdesivir for treating Covid-19

The recommendation is a blow to Gilead's drug, which was one of the first thought to offer a meaningful benefit to coronavirus patients after a study showed it reduced their recovery time

Top intensive care body advises against Remdesivir for Covid-19 patients

Debate continues to rage in the medical industry about which drugs are best to treat Covid-19 patients

DCGI rejects DRL's proposal, denies full marketing rights for Remdesivir

Emergency use authorisation to continue; recently, WHO had raised doubts about efficacy of drug in treatment of Covid-19 patients

USFDA approves Remdesivir as first Covid-19 therapy amid WHO reservations

Approval unlikely to increase prices immediately as Gilead has said licenses are royalty-free until the end of the health emergency

Remdesivir, HCQ don't aid much in recovery of Covid-19 patients: WHO trials

While Gilead calls for review, the findings can have significant impact on the growing demand of remdesivir

Europe buys 500,000 courses of Gilead's remdesivir amid supply worries

Several European countries have said they are experiencing shortages of the drug, whose global stock has been secured almost entirely by the United States

Covid-19: Liquid form of remdesivir to smoothen supply, says industry

Multiple manufacturers confirmed that the liquid form of the injectable would shorten the manufacturing process

Gilead Sciences to pay $97 million to settle US govt kickback probe

Gilead's actions enabled the Foster City, California-based drugmaker to boost revenue, ran from June 2007 to December 2010, and violated the federal False Claims Act

Gilead to buy cancer drugmaker Immunomedics Inc for $21 billion

Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug